CSL’s reduced guidance, impairment, weigh heavy on stock price

CSL Limited said its core business remains stable with strong demand across key products. The company is also focusing on improving efficiency and supporting future growth.

CSL Limited (ASX: CSL) 

on 11 May 2026 shared its Interim CEO 90 Day Review and Financial Update. 
The recent product launches are beginning to improve patient demand and commercial performance. The company is also simplifying operations to reduce complexity and improve efficiency across different divisions. Cost reduction programs and transformation activities are continuing as planned.

CSL said the industry remains stable with long-term growth opportunities still available. The company highlighted its strong position in plasma collections and influenza vaccines. At the same time management acknowledged that expected financial benefits from current growth initiatives are taking longer to appear. Because of this the company lowered its FY26 guidance.

Outlook

CSL now expects FY26 revenue to be around $15.2 billion on a constant currency basis. NPATA excluding restructuring costs and impairments is expected to be around $3.1 billion.
A major reason for the lower guidance is the U.S. Immunoglobulin business. Demand continues to grow at a healthy mid to high single digit rate. Though, revenue will be affected by the normalisation of channel inventory which is expected to reduce revenue by about $300 million.

The Albumin business in China also impacted the outlook. CSL said its market share improved and sales volumes stabilised but the overall market value declined. This is expected to lower revenue by around $200 million.

Additional pressure came from the Middle East conflict slower HEMGENIX growth expectations and increased competition in iron products. Together these factors are expected to reduce revenue by another $150 million. Despite these challenges CSL still expects second half revenue growth for CSL Behring while CSL Seqirus is projected to perform slightly better than previously expected.

Asset impairments and expected charges

The company announced that it expects approximately $5 billion in additional non-cash pre-tax impairments across FY26 and FY27. These charges are separate from the impairments already disclosed during the FY26 half-year results.

The additional impairments mainly relate to CSL Vifor intangible assets including parts of its product portfolio. The company also identified under-utilised property plant and equipment that will be included in the impairment review.

CSL stated that these figures are still subject to further analysis business developments external audit review and final Board approval. A further update will be provided during the FY26 full year results announcement on 18 August 2026.

Future plans

The review identified several areas that affected the company’s recent performance. Historical growth expectations were not achieved and competitors strengthened their capabilities over time. The company also faced limited innovation in its pipeline along with several Phase 3 trial failures.
To improve future performance CSL plans to focus more on lifecycle management new treatment approaches and strategic partnerships. Research and development commercial operations medical affairs and business development functions are being restructured to improve execution and accountability.

CSL also admitted that rising costs were not addressed quickly enough and operational decision making became too centralised. Infrastructure investment increased faster than earnings and the CSL Vifor acquisition delivered weaker results than expected. 

(Source: Company Report)